FDMT
4d Molecular Therapeutics Inc
$25.3
Earnings Summary
Revenue | $-0.02Mn |
Net Profits | $-32.28Mn |
Net Profit Margins | 169910.53% |
Highlights
4d Molecular Therapeutics Inc’s revenue fell -101.52% since last year same period to $-0.02Mn in the Q4 2023. On a quarterly growth basis, 4d Molecular Therapeutics Inc has generated -100.09% fall in its revenue since last 3-months.
4d Molecular Therapeutics Inc’s net profit fell -18.37% since last year same period to $-32.28Mn in the Q4 2023. On a quarterly growth basis, 4d Molecular Therapeutics Inc has generated -214.77% fall in its net profits since last 3-months.
4d Molecular Therapeutics Inc’s net profit margin jumped 7868.8% since last year same period to 169910.53% in the Q4 2023. On a quarterly growth basis, 4d Molecular Therapeutics Inc has generated 334818.44% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the 4d Molecular Therapeutics Inc post its latest quarter earnings
EPS Estimate Current Quarter | -0.72 |
EPS Estimate Current Year | -0.72 |
Highlights
4d Molecular Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.72 - a 2.7% jump from last quarter’s estimates.
4d Molecular Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.72.
Key Ratios
Key ratios of the 4d Molecular Therapeutics Inc post its Q4 2023 earnings
Earning Per Share (EPS) | -0.75 |
Highlights
4d Molecular Therapeutics Inc’s earning per share (EPS) jumped 10.71% since last year same period to -0.75 in the Q4 2023. This indicates that the 4d Molecular Therapeutics Inc has generated 10.71% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2023-05-11 | -0.89 | -0.88 | 1.12% |
2023-08-09 | -0.81 | -0.77 | 4.94% |
2024-02-29 | -0.74 | -0.75 | -1.35% |
2023-11-09 | -0.59 | -0.24 | 59.32% |
₹0 US Stocks a/c Opening Fee